skip to main content

BRAF+MEK Response Kinetics — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardMelanoma & SkinBRAF+MEK Response KineticsSCE Medical Oncology

A patient with BRAF V600-mutant melanoma takes encorafenib 450 mg daily plus binimetinib. Binimetinib must be interrupted for ocular toxicity, but encorafenib can continue. What adjustment is specified?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — Reduce encorafenib to 300 mg daily during the binimetinib interruption

When binimetinib is temporarily interrupted, encorafenib should be reduced from 450 mg to 300 mg daily. If binimetinib is permanently discontinued, encorafenib should also be discontinued. Temporary interruption therefore differs from both unchanged full-dose monotherapy and permanent cessation.

Reference: Braftovi 75 mg UK SmPC. https://www.medicines.org.uk/emc/product/9500/smpc